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Abstract 
Introduction. According to the World Health Organization (WHO), in 2017 about 10 
million people became ill with TB in the world. Also, WHO reports that Ukraine belongs to 
countries where the number of patients with chemo-resistant tuberculosis (HRTB) is one of 
the largest in the world. In 2017, TB caused 1.6 million deaths, of which 300,000 had a 
combined HIV/TB infection. 
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The purpose and tasks of the study. To study the hematologic changes in patients 
co-infected HRTB / HIV at the level of CD4 + lymphocytes 200 - 50 cells/ml and evaluate the 
effectiveness of immunoglobulin therapy. 
Materials and methods. The study involved 52 patients with combined HRTB / HIV 
disease, aged 20 to 55 years. The study of hematological parameters was performed on the 
basis of the laboratory of the Odessa regional anti-tuberculosis dispensary, the calculation was 
performed on the automatic hematological analyzer Sysmex ХР-300 3-diff with direct 
counting of neutrophils (Japan). 
Results and discussion. In patients with HRTB / HIV with a level of CD4 + 
lymphocytes below 200 cells / μl, hematological parameters before the start of anti-TB 
therapy were characterized by the fact that patients of both groups were more likely to have 
leukocytosis than leukopenia, that is: 3.5 times more often in patients in group 1 (26.9% vs. 
7.7%), and 9.1 times in the 2nd group (34.6% vs. 3.8%); lymphopenia - 2 times higher than 
lymphocytosis in group 1 and the same expressed in group 2 (see table). Monocytopenia was 
noted in 3.8%, monocytosis was registered 4 times more often in group 1, and in 1.5 times - in 
the 2nd. The frequency of eosinophilia reached 15.4% and 11.5%, in the first and second 
groups, respectively. Increases in neutrophils occurred in 30.8% and 38.5% of patients in 
groups 1 and 2, respectively. 
Lung anemia was registered more often in both groups than anemia of average grade - 
2 times more often in the 1 st (46.2% vs. 23.1%), and the second group (53.8% vs. 26.9%) , 
and severe anemia was 3.8% in the 1st group and 7.7% in the second group of the subjects. 
Thrombocytopenia was diagnosed in 23.1% and 19.2% of patients in groups 1 and 2. 
Increasing the rate of erythrocyte sedimentation was determined in a greater number of 
patients - 69.2% of the examined group 1 and 65.4% of the 2nd group. 
Conclusions. After the use of intravenous IgG in the combination therapy of patients 
with HRTB/HIV, there was a significant reduction in the manifestations of inflammation and 
infectious activity compared with patients taking only anti-TB drugs and ARVT according to 
treatment standards. 
Key words: chemo-resistant tuberculosis, HIV-infection, hematologic changes. 
 
Introduction. The most important problem is that worldwide tuberculosis (TB) is one 
of the first ten causes of death [3]. According to the World Health Organization (WHO), in 
2017 about 10 million people became ill with TB in the world. Also, WHO reports that 
Ukraine belongs to countries where the number of patients with chemo-resistant tuberculosis 
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(HRTB) is one of the largest in the world. In 2017, TB caused 1.6 million deaths, of which 
300,000 had a combined HIV/TB infection [8]. 
According to the Center for Public Health of the Ministry of Health of Ukraine for the 
first 9 months of 2018, the highest levels of HIV infection in Ukraine were registered in 
Dnipropetrovsk (78.9 per 100,000 population), Odesa (74.3), Mykolaiv (55.5) Oblasts, Kyiv 
(48.7), Kyiv (40.1), Kirovograd (38.6), Chernihiv (37.5), Kherson (36.6) oblasts. During 9 
months of 2018, 2361 cases of AIDS deaths were registered, compared to 2,248 cases for the 
corresponding period of last year. The AIDS mortality rate was 5.6 and 5.3 per 100,000 
population, respectively. The rate of growth of the indicator was + 5.7%. The highest levels of 
AIDS deaths were registered in Dnipropetrovsk (18.6 per 100,000 population), Odesa (10.3), 
Kirovograd (9.4), Mykolaiv (8.9) oblasts and Kyiv (6.5) [1]. 
The purpose and tasks of the study. To study hematological changes in patients with 
co-infection of HRTB/HIV at a level of CD4 + lymphocytes 200 - 50 cells/μl and to evaluate 
the effectiveness of immunoglobulin therapy. 
Materials and methods. The study involved 52 patients with combined HRTB/HIV 
disease, aged 20 to 55 years. The study of hematological parameters was performed on the 
basis of the laboratory of the Odessa regional anti-tuberculosis dispensary, the calculation was 
performed on the automatic hematological analyzer Sysmex ХР-300 3-diff with direct 
counting of neutrophils (Japan). Use the volume of specimens of 50 μl of whole blood, or 20 
μl in pre-dilution mode. For the study, DC method was used in a fixed volume: WBC, RBC / 
PLT, and non-cyanide hemoglobin determination (HGB). Quality control: internal (60 graphs, 
6 QC files) and daily external (IQAS Online via SNCS), control blood Eightcheck-3WP. 
Reagents CELLPACK (diluent), volume 20 l, Stromatolyser-WH (lysis solution), 3 vials of 
500 ml, Cellclean (cleansing solution), 50 ml. Control materials: EIGHTCHECK®-3WP-N, 
1.5 ml, EIGHTCHECK®-3WP-L, 1.5 ml, EIGHTCHECK®-3WP-H, 1.5 ml. 
To achieve the purpose of the work, patients with HRTB/HIV with a CD4 + 
lymphocyte level below 200 cells/μl, but above 50 cells/μl were selected, and divided into 2 
groups: 
- Group 1(control) - 26 patients with HRTB/HIV with a level of CD4 + lymphocytes 
below 200 cells/μl, but above 50 cells/μl receiving standard treatment for second-line 
antiretroviral therapy (ARVT); 
- Group 2 (basic) 26 patients with HRTB/HIV with a level of CD4 + lymphocytes 
below 200 cells/μl but above 50 cells/μl receiving additional intravenous immunoglobulin 
IgG in a complex therapy (5% solution for intravenous infusion 50 ml, Biofarma, Ukraine).  
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Results of analysis of literary sources. Hematologic changes play an important role 
in the pathogenesis of TB/HIV co-infection, which can be one of the immediate causes of the 
lethal outcome of HRTB/HIV patients, and also prevent the use of ARVT in the early stages 
of TB treatment because it complicates its management, especially in patients with 
pronounced immunosuppression (with a level of CD4 + lymphocytes below 200 cells/μl) [4, 
6, 9]. 
In late stages of HIV, in combination with HRTB, haematological changes arise due to 
bone marrow obesity due to the formation of its atrophy and even necrosis. There are 
dysplastic changes, which according to clinical and laboratory characteristics resemble 
myeloplasty syndrome [2, 7]. Due to severe hematological disorders, there is a need to change 
the treatment plan and its supplements with new pathogenetic agents that will contribute not 
only to the improvement of white and red blood, but also to reduce the toxicity burden in 
general and to reduce the risk of developing of systemic inflammatory response a syndrome 
(SIRS) [5, 8, 10]. 
Discussion of the results of their own research. In patients with HRTB/HIV with a 
level of CD4 + lymphocytes below 200 cells/μl, hematological parameters before the start of 
anti-TB therapy were characterized by the fact that patients of both groups were more likely 
to have leukocytosis than leukopenia, that is: 3.5 times more often in patients in group 1 
(26.9% vs. 7.7%), and 9.1 times in the 2nd group (34.6% vs. 3.8%); lymphopenia - 2 times 
higher than lymphocytosis in group 1 and the same expressed in group 2 (see table). 
Monocytopenia was noted in 3.8%, monocytosis was registered 4 times more often in group 
1, and in 1.5 times - in the 2nd. The frequency of eosinophilia reached 15.4% and 11.5%, in 
the first and second groups, respectively. Increases in neutrophils occurred in 30.8% and 
38.5% of patients in groups 1 and 2, respectively. 
Lung anemia was registered more often in both groups than anemia of average grade - 
2 times more often in the 1 st (46.2% vs. 23.1%), and the second group (53.8% vs. 26.9%), 
and severe anemia was 3.8% in the 1st group and 7.7% in the second group of the subjects. 
Thrombocytopenia was diagnosed in 23.1% and 19.2% of patients in groups 1 and 2. 
Increasing the rate of erythrocyte sedimentation was determined in a greater number of 
patients - 69.2% of the examined group 1 and 65.4% of the 2nd group. 
During treatment, the following hematologic dynamics was observed (see table). 
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Table 
Dynamics of hemogram index of patients with HRTB/HIV with CD4+ <200 cells/μl but >50 cells/μl in intensive phase 
 
Indicator      
 
 
      A group of patients 
0 month 2 weeks 1 month 2 month /3 month 4 month  5 month 6/7/8 month 
abs Q±mq
% 
abs Q±mq% abs Q±mq% abs Q±mq% abs Q±mq% abs Q±mq% abs Q±mq% 
Leuko-
cytosis 
TG-1 
(n=26) 
7 26,9 
±1,77 
10 38,5 
±1,95 
12 46,2 
±1,99 
11/13 42,3±1,98/ 
50,0±2,02 
8 30,8 
±1,85 
6 23,1 
±1,69 
3/1/1 11,5±/ 1,28/ 
3,8±0,76/ 
3,8±0,76 
TG-2 
(n=26) 
9 34,6 
±1,90 
3 11,5** 
±1,28 
3 11,5** 
±1,28 
1/1 3,8±0,76***/ 
3,8±0,76*** 
0 0±0*** 0 0±0*** 0/0/0 0±0***/0±0**/ 
0±0** 
Leukopenia TG-1 
 (n=26) 
2 7,7 
±1,58 
4 15,4* 
±1,77 
3 11,5** 
±1,85 
2/0 7,7±1,07***/
0±0*** 
0 0±0*** 0 0±0*** 0/0/0 0±0***/0±0*/ 
0±0* 
TG-2 
 (n=26) 
1 3,8* 
±0,76 
8 30,8 
±1,85 
14 53,8 
±1,99 
12/10 46,2±1,99/ 
38,5±1,95 
7 26,9 
±1,77 
4 15,4 
±1,44 
2/1/1 7,7±1,07/ 
3,8±0,76/ 
3,8±0,76 
 
Lympho-
cytosis 
TG-1 
 (n=26) 
1 3,8* 
±0,76 
3 11,5* 
±1,28 
2 7,7*** 
±1,07 
5/4 19,2±1,58*/ 
15,4±1,44** 
3 11,5 
±1,28 
2 7,7 
±1,07 
1/1/0 3,8±0,76*/ 
3,8±0,76/ 
0±0 
TG-2 
 (n=26) 
2 7,7 
±1,07 
9 34,6 
±1,90 
11 42,3 
±1,98 
10/13 38,5±1,95/ 
50,0±2,02 
5 19,2 
±1,58 
3 11,5 
±1,28 
2/0/0 7,7±1,07/ 
0±0**/ 
0±0 
Lympho-
penia 
TG-1 
(n=26) 
2 7,7 
±1,07 
7 26,9 
±1,77 
9 34,6 
±1,90 
9/12 34,6±1,90/ 
46,2±1,99 
8 30,8 
±1,85 
7 26,9 
±1,77 
4/ 4/1 15,4±1,44/ 
15,4±1,44/ 
3,8±0,76 
TG-2 
 (n=26) 
2 7,7 
±1,07 
1 3,8 
±0,76*** 
1 3,8 
±0,76*** 
1/0 3,8±0,76***/ 
0±0** 
0 0 
±0*** 
0 0±0*** 0/0/0 0±0***/0±0***/ 
0±0* 
Mono-
cytosis 
TG-1 
(n=26) 
4 15,4 
±1,44 
4 15,4 
±1,44* 
6 23,1* 
±1,69 
7/9 26,9±1,77*/ 
34,6±1,90* 
4 15,4* 
±1,44 
2 7,7* 
±1,07 
1/0/0 3,8±0,76*/ 
0±0*/ 
0±0 
TG-2 
 (n=26) 
3 11,5 
±1,28 
8 30,8 
±1,85 
10 38,5 
±1,95 
11/14 42,3±1,98/ 
53,8±1,99 
6 23,1 
±1,69 
4 15,4 
±1,44 
2/1/0 7,7±1,07/ 
3,8±0,76/ 
0±0 
Monocyto-
penia 
TG-1 
 (n=26) 
1 3,8* 
±0,76 
3 11,5 
±1,28 
4 15,4 
±1,44 
4/7 15,4±1,44/ 
26,9±1,77 
5 19,2 
±1,58 
3 11,5 
±1,28 
3/2/1 11,5±1,28/ 
7,7±1,07/ 
3,8±0,76 
TG-2 
 (n=26) 
2 7,7 
±1,07 
2 7,7 
±1,07 
1 3,8** 
±0,76 
1/0 3,8±0,76**/ 
0±0*** 
0 0±0*** 0 0±0*** 0/0/0 0±0***/0±0***/ 
0±0* 
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Eosino-
philia 
TG-1 
 (n=26) 
4 15,4 
±1,44 
6 23,1 
±1,69 
7 26,9 
±1,77 
7/8 26,9±1,77/ 
30,8±1,85 
5 19,2 
±1,58 
3 11,5 
±1,28 
2/2/1 7,7±1,07/ 
7,7±1,07/ 
3,8±0,76 
TG-2 
 (n=26) 
3 11,5 
±1,28 
1 3,8*** 
±0,76 
1 3,8*** 
±0,76 
0/0 0±0***/ 
0±0*** 
0 0±0*** 0 0±0*** 0/0/0 0±0***/0±0***/ 
0±0* 
Neutro-
philia 
TG-1 
 (n=26) 
8 30,8 
±1,85 
13 50 
±2,02 
15 57,7 
±1,98 
14/17 53,8±1,99/ 
65,4±1,90 
10 38,5 
±1,95 
6 23,1 
±1,69 
4/3/2 15,4±1,44/ 
11,5±1,28/ 
7,7±1,07 
TG-2 
 (n=26) 
10 38,5 
±1,95 
3 11,5 
±1,28** 
2 7,7 
±1,07*** 
2/1 7,7±1,07***/ 
3,8±0,76*** 
1 3,8*** 
±0,76 
0 0±0*** 0/0/0 0±0***/ 
0±0***/0±0*** 
Anemia 
light 
weight 
TG-1 
 (n=26) 
12 46,2 
±1,99 
11 42,3 
±1,98 
8 30,8 
±1,85 
7/5 26,9±1,77/ 
19,2±1,58 
6 23,1 
±1,69 
5 19,2±1,58 4/3/3 15,4±1,44/ 
11,5±1,28/ 
11,5±1,28 
TG-2 
 (n=26) 
14 53,8 
±1,99 
10 38,5 
±1,95 
7 26,9 
±1,77 
2/1 7,7±1,07**/ 
3,8±0,76** 
2 7,7 
±1,07** 
1 3,8 
±0,76*** 
1/0/0 3,8±0,76**/ 
0±0***/0±0*** 
Anemia 
medium 
TG-1 
 (n=26) 
6 23,1 
±1,69 
7 26,9 
±1,77 
9 34,6 
±1,90 
9/8 34,6±1,90/ 
30,8±1,85 
4 15,4 
±1,44 
2 7,7 
±1,07 
0/0/0 0±0/ 
0±0/0±0 
TG-2 
 (n=26) 
7 26,9 
±1,77 
5 19,2 
±1,58 
3 11,5 
±1,28** 
3/1 11,5±1,28**/ 
3,8±0,76*** 
0 0±0*** 0 0±0*** 0/0/0 0±0/ 
0±0/0±0 
Anemia 
heavy 
TG-1 
 (n=26) 
1 3,8 
±0,76* 
1 3,8 
±0,76 
2 7,7 
±1,07 
2/1 7,7±1,07/ 
3,8±0,76 
1 3,8 
±0,76 
0 0 
±0 
0/0/0 0±0/ 
0±0/0±0 
TG-2 
 (n=26) 
2 7,7 
±1,07 
1 3,8 
±0,76 
1 3,8* 
±0,76 
0/0 0±0***/0±0* 0 0±0* 0 0±0 0/0/0 0±0/0±0/0±0 
Thrombo-
cytopenia 
TG-1 
 (n=26) 
6 23,1 
±1,69 
8 30,8 
±1,85 
8 30,8 
±1,85 
10/ 
11 
38,5±1,95/ 
42,3±1,98 
7 26,9 
±1,77 
4 15,4 
±1,44 
2/1/1 7,7±1,07/ 
3,8±0,76/ 
3,8±0,76 
TG-2 
 (n=26) 
5 19,2 
±1,58 
3 11,5 
±1,28** 
4 15,4 
±1,44* 
2/1 7,7±1,07**/ 
3,8±0,76*** 
1 3,8 
±0,76**
* 
0 0±0*** 0/0/0 0±0***/ 
0±0*/0±0* 
Increased 
ESR 
TG-1 
 (n=26) 
18 69,2 
±1,85 
19 73,1 
±1,77 
21 80,8 
±1,58 
21/22 80,8±1,58/ 
84,6±1,44 
20 76,9 
±1,69 
15 57,7 
±1,98 
12/11/
8 
46,2±1,99/ 
42,3±1,98/ 
30,8±1,85 
TG-2 
 (n=26) 
17 65,4 
±1,90 
18 69,2 
±1,85 
14 53,8 
±1,99* 
10/11 38,5±1,95*/ 
42,3±1,98* 
8 30,8 
±1,85* 
6 23,1 
±1,69* 
4/3/3 15,4±1,44*/ 
11,5±1,28**/ 
11,5±1,28* 
 
* - significant difference indices 1 and 2 groups (p <0.05) 
** - significant difference indices 1 and 2 groups (p <0.01) 
*** - significant difference indices 1 and 2 groups (p <0.001) 
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In 38.5% (± 1.95) of patients in group 1 (control) who received standard treatment with 
second-line anti-TB drugs with ARVT, a gradual increase in the frequency of leukocytosis, which 
in 1 month. registered at 46.2%, after 3 months - at 50%, but after 4 months. there was a steady 
decrease of it by 1.6 times to the level of 30.8% and after 5 months in 2 times - to 23.1%). At the 
end of 8 months the treatment of leukocytosis was maintained in 3.8% of patients (see table). 
In patients with 2 groups who additionally received intravenous IgG in combination therapy, 
after 2 weeks of treatment the frequency of leukocytosis decreased 3-fold and amounted to 11.5% 
(p <0.01) with a stable decrease in this index after the 1, 2, 3 month. to 3.8% and absence of signs 
of leukocytosis during the last 4 to 8 months of surveillance, which was a sign of early decline in 
the activity of the inflammatory process. 
At the same time, after 2 weeks of treatment, the frequency of leukopenia in patients of the 
1st group increased almost 2 times (from 7.7% to 15.4%) and gradually decreased after the 1 st 
month of treatment with 11.5% to 6% in the 3rd month, since the 4th month was not noted in any of 
the patients (see tab.). 
However, the frequency of leukopenia in patients from the 2nd group from the 2nd week 
was significantly more frequent than in the control (8 times versus 2 in 1 group) and reached 30.8% 
of cases and remained at a high level (53.8% 46.2%) to 3rd month. surveillance inclusive. Studies 
conducted after the 3rd and 5th months showed a marked rate of decrease in the frequency of 
leukopenia from 38.5% to 15.4%, and after 6 - 8 months. - from 7.7% to 3.8%, respectively. 
Lymphocytosis increased (p <0,05) simultaneously in patients of both the 1st and 2nd 
groups, but from the 1st month. treatment - more progressively in patients in the 2nd group, which 
reached the values of 42.3%, while in the control - 7.7% (table 2). 
It should be emphasized that in patients with the first group, the high frequency of 
lymphopenia was maintained throughout the observation time (7.7 - 26.9 - 34.6 - 34.6 - 46.2 - 30.8 - 
26.9)%, and only after the 8th month. this indicator dropped to 3.8% (one case remained) (see tab.). 
In patients of the 2nd group there was an early and rapid decrease in the frequency of 
lymphopenia: from the end of the 2nd week to the 2nd month of observation in 2 times (p <0.001), 
with the remainder only 1 case (3.8%), but with 3 months later limfopenia was not determined. 
The content of monocytes in patients from the 2nd group from the second week to the end of 
the third month increased by 4.8 times, and after 3rd month. it was gradually decreasing, and 
amounted to 15.4% for the 5th month and 3.8% for the 7th month (see table). 
The high frequency of monocytopenia (26.9%) was observed in patients of the 1st group 
until the 3rd month of treatment, and decreased after the 4th month to 19.2%, the 7th - to 7.7% and 
the 8th - to 3.8% (1 case). 
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The number of eosinophils increased up to 3 months of treatment, including 30.8% of 
patients in group 1, while among patients in the second group of eosinophilia after the first 2 weeks, 
significantly (to 3.8%) decreased, and after 1 month was absent in the future (by the end of 8 
months) was not registered (see table). 
Frequency of neutrophilia in patients in the control group remained stable throughout the 
entire period of observation. In patients of the 2 nd group - this figure has decreased already after 2 
weeks in 3,3 times, after the first month of treatment - in 5, and 3rd month. - 10 times (p <0,001). 
On the part of red blood, the majority of patients in both groups experienced anemia (73.1% 
to 88.4% of the 1st and 2nd groups). The performed treatment showed that anemia of mild grade in 
patients of group 1 was determined in 46.2% and remained until the end of 6 months. at the level of 
15.4% and only after 8 months. decreased to 11.5%. 
At the same time, patients in the 2nd group experienced a decrease in the frequency of 
anemia of mild degree from 53.8% to 38.5% after the first month. therapy with subsequent 
reduction of cases at the end of the 2nd month. and absence after 7th month (p <0.001). The 
incidence of middle-level anemia in the continuation of treatment was more active (p <0.01) also 
decreased in patients in the second group (see table). 
Severe anemia regressed in patients with 2nd group 2 times faster (according to results of 
studies after 1-2-th and 3rd months of observation) than in patients with control group (p <0,05). 
Thrombocytopenia also longer recorded in the patients of group 1 and after 3 months of 
treatment was maintained in 42.3% of subjects. 
In patients of the 2nd group, thrombocytopenia was noted with each month in a significantly 
smaller number of patients, and after the 2nd and 3rd months. was 7.7 ± 1.07% and 3.8 ± 0.76% 
respectively, which is 5 and 11 times lower than in the control group. Subsequently, starting with 6 
months of treatment, thrombocytopenia was not registered in any patient (see table). 
The increase in ESR was registered in more than 2/3 patients in both groups of observation. 
Treatment for 4 months of patients in group 1 (according to the standard scheme) did not lead to a 
positive dynamics of elevated ESR. However, in patients with 2 groups, in the 2 weeks of treatment, 
a decrease in the number of cases of elevated ESR (to 57.7%) was noted, with a progressive 
reduction of its percentage with each month (up to 23.1%); at the 5th month of treatment, this figure 
was 2.5 times lower than in group 1 (see table). 
Thus, the results reflected a significant decrease in the activity of an infectious inflammation 
in patients who used additionally Ig G compared with patients treated by commonly accepted 
standard method (anti-TB drugs and ARVT) therapy in patients with HRTB/HIV. 
Conclusions 
1. In patients with HRTB/HIV with a level of CD4 + lymphocytes 200 - 50 cells/μl, 
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systemic haematological changes were detected: leukocytosis was determined more often (from 3.5 
to 9 times) than leukopenia; lymphopenia - 2 times higher than lymphocytosis; monocytosis was 
registered 4 times more often than monocytopenia; neutrophilosis was present in 1/3 of cases with 
not frequent eosinophilia (11.5 - 15.4%); thrombocytopenia was diagnosed in 23,1% of cases; 
anemia of mild degree - in 1/2 patients, the average degree - in 2 times less often and only in one 
patient - severe form; in 2/3 of patients, an increase in ESR was determined. 
2. Following the use of intravenous IgG in the combination therapy of patients with HRTB / 
HIV, there was a significant reduction in the manifestations of inflammatory process and infectious 
activity compared with patients taking only anti-TB drugs and ARVT according to treatment 
standards. 
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